Lysophosphatidylcholine - Biomarker of metformin action: Studied using UPLC/MS/MS

Biomedical Chromatography

Volumn 23, Issue 7, 2009, Pages 782-786

  Cai, Shuang ^a,b   Huo, Taoguang ^a   Li, Ning ^a   Xiong, Zhili ^a   Li, Famei ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Biomarkers; Lysophosphatidylcholine; Metabonomics; Metformin; UPLC MS MS

Indexed keywords

DRUG PRODUCTS; METABOLITES; MULTIVARIANT ANALYSIS;

ENDOGENOUS METABOLITES; HEALTHY VOLUNTEERS; LYSOPHOSPHATIDYLCHOLINE; METABOLITE PROFILES; METABOLITE PROFILING; METABONOMICS; METFORMINS; MULTIVARIATE STATISTICS; PLASMA METABOLITES; UPLC-MS/MS;

BIOMARKERS;

ION; LYSOPHOSPHATIDYLCHOLINE; METFORMIN; BIOLOGICAL MARKER;

ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; FRAGMENTATION REACTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN EXPERIMENT; ION CURRENT; LIQUID CHROMATOGRAPHY; METABONOMIC; NORMAL HUMAN; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ADULT; BLOOD; CHEMISTRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; METABOLISM; METHODOLOGY; MULTIVARIATE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS;

ADULT; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LYSOPHOSPHATIDYLCHOLINES; MALE; METFORMIN; MULTIVARIATE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; TANDEM MASS SPECTROMETRY;

EID: 70149117058     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1185     Document Type: Article

References (18)

1. Bollard ME, Stanley EG, Lindon JC, Nicholson JK and Holmes E. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR in Biomedicine 2005; 18: 143-162.
2. Castro-Perez J, Plumb R and Liang L. A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition. Rapid Communications in Mass Spectrometry 2005; 19: 798-804.
3. Chen M, Su M, Zhao L, Jiang J, Liu P, Cheng J, Lai Y, Liu Y and Jia W. Metabonomic Study of Aristolochic Acid-Induced Nephrotoxicity in Rats. Journal of Proteome Research 2006; 5: 995-1002.
4. Cusi K and DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Reviews 1998; 6: 89-131.
5. Gika HG, Theodoridis GA, Wingate JE and Wilson ID. Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. Journal of Proteome Research 2007; 6: 3291-3303.
6. Kirpichnikov D, McFarlane SI and Sowers JR. Metformin: an update. Annals of internal medicine 2002; 137: 25-33.
7. Krentz AJ and Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411.
8. Lindon JC, Keun HC, Ebbels TM, Pearce JM, Holmes E and Nicholson JK. The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievement. Pharmacogenomics 2005; 6: 691-699.
9. Lord JM, Flight IH and Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ (Clinical Research) 2003; 327: 951-955.
10. Nicholson JK, Connelly J, Lindon JC and Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nature Review Drug Discovery 2002; 1: 153-161.
11. Nicholson JK, Holmes E and Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nature Review Microbiology 2005; 3: 431-438.
12. Robertson DG, Reily MD, Sigler RE, Wells DF, Paterson DA and Braden TK. Metabonomics: evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. Toxicological Sciences 2000; 57: 326-337.
13. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M and Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Systematic Reviews 2005; 20: CD002966.
14. Wang C, Kong H, Guan Y, Yang J, Gu J, Yang S and Xu G. Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Analytical Chemisty 2005a; 77: 4108-4116.
15. Wang C, Xie S, Yang J, Yang Q and Xu G. Structural identification of human blood phospholipids using liquid chromatography/quadrupole-linear ion trap mass spectrometry. Analytica Chimica Acta 2005b; 525: 1-10.
16. Wanninger J, Neumeier M, Weigert J, Liebisch G, Weiss TS, Schäffler A, Aslanidis C, Schmitz G, Schölmerich J and Buechler C. Metformin reduces cellular lysophosphatidylcholine and thereby may lower apolipoprotein B secretion in primary human hepatocytes. Biochimica et Biophysica Acta 2008; 1781: 321-325.
17. Williams RE, Lenz EM, Evans JA, Wilson ID, Granger JH, Plumb RS and Stumpf CL. A combined (1)H NMR and HPLC-MS-based metabonomic study of urine from obese (fa/fa) Zucker and normal Wistar-derived rats. Journal of Pharmaceutical and Biomedical Analysis 2005; 38: 465-471.
18. Yang J, Xu G, Zheng Y, Kong H, Pang T, Lv S and Yang Q. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result form hepatitis and hepatocirrhosis diseases. Journal of Chromatography B 2004; 813: 59-65.